Monday, 24 September, 2018

Medical research company selling business for $800M

Ned Pagliarulo  Bio Pharma Dive Ned Pagliarulo Bio Pharma Dive
Melinda Barton | 16 February, 2018, 06:55

Therefore 70% are positive. Charles River Laboratories has $124 highest and $65 lowest target. Royal Bank of Canada set a $116.00 price target on Charles River Laboratories Intl. and gave the stock a "hold" rating in a report on Tuesday. Piper Jaffray maintained the shares of FRAC in report on Thursday, December 21 with "Buy" rating. The rating was maintained by Citigroup with "Neutral" on Thursday, October 5. (NYSE:CRL) on Tuesday, April 26 with "Buy" rating. BMO Capital Markets has "Hold" rating and $20.0 target. The rating was maintained by Barclays Capital on Friday, May 20 with "Underweight".

As pharma companies increasingly rely on outsourced services to improve efficiency and access to expertise they no longer maintain in-house, Charles River need additional capacity to accommodate the demand, he told investors earlier today. (NYSE:CRL) [Trend Analysis] luring active investment momentum, shares an increase 3.44% to $111.36. (NYSE:FRAC) earned "Buy" rating by Citigroup on Tuesday, February 13. About 380,558 shares traded or 4.24% up from the average. It represents the number of a stock's shares that are being shorted by investors.

The stock decreased 1.23% or $1.36 during the last trading session, reaching $108.95. About 343,467 shares traded. CDK Global, Inc. (NASDAQ:CDK) has risen 18.92% since February 15, 2017 and is uptrending.

Investors sentiment increased to 1.46 in Q3 2017. Its down 0.29, from 1.18 in 2017Q2. Trexquant Investment Lp sold 5,456 shares as the company's stock declined 6.12% while stock markets rallied.

Several other hedge funds and other institutional investors also recently made changes to their positions in CRL. Private Trust Na accumulated 4,326 shares.

On 1/18/2018 Online Communications Bdirect, Director, sold 131,000 with an average share price of $0.29 per share and the total transaction amounting to $37,990.00. Meeder Asset Management Inc acquired 4,767 shares as Charles River Laboratories Int (CRL)'s stock rose 1.24%. Thrivent Financial For Lutherans owns 392,372 shares. Natixis invested in 7,264 shares or 0% of the stock. (NYSE:CRL). Private Trust Na owns 4,326 shares or 0.1% of their United States portfolio. Fifth Third Bank holds 100 shares. (NYSE:GPS) stake by 14,390 shares to 38,692 valued at $1.14 million in 2017Q3.

Among 10 analysts covering Keane Group Inc (FRAC), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 33% are positive. Charles River Laboratories had 45 analyst reports since August 3, 2015 according to SRatingsIntel. The company was maintained on Thursday, August 4 by Citigroup. SunTrust upgraded the shares of HIW in report on Wednesday, September 9 to "Buy" rating.

1/18/2018-Evercore ISI initiated coverage with a In rating. RBC Capital Markets maintained the shares of NDSN in report on Wednesday, August 24 with "Sector Perform" rating. The company was upgraded on Thursday, January 7 by Wells Fargo. The rating was maintained by Robert W. Baird on Friday, January 8 with "Outperform".

Nordson Corporation engineers, manufactures, and markets products and systems to dispense, apply, and control adhesives, coatings, polymers, sealants, biomaterials, and other fluids. It has a 53.73 P/E ratio. This segment also offers automated adhesive dispensing systems for packaged goods industries; and components and systems used in the thermoplastic melt stream. Smith David Ross sold 2,552 shares worth $171,228. 12,142 shares were sold by Hilton Michael F, worth $1.82 million on Friday, January 5. (NYSE:CRL) for 756,078 shares.

Since August 14, 2017, it had 0 insider purchases, and 4 selling transactions for $4.07 million activity. JOHST DAVID P also sold $2.72 million worth of Charles River Laboratories International, Inc. YorkBridge Wealth Partners LLC lifted its position in Charles River Laboratories 445.5% during the 3rd quarter. This nets out to an increase of 197284 shares and is a bullish sign for CRL. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Charles River Laboratories 2.2% in the second quarter. During the same quarter previous year, the business earned $1.21 EPS. sell-side analysts forecast that Charles River Laboratories Intl. Barbo William D sold $399,632 worth of stock or 4,000 shares.

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. It operates through three divisions: Research Models and Services, Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).